The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

• Anne Kleijn,

  Affiliation Dept of Neurosurgery, Brain Tumor Center, ErasmusMC, Rotterdam, The Netherlands

  ⨯
• Jenneke Kloezeman,

  Affiliation Dept of Neurosurgery, Brain Tumor Center, ErasmusMC, Rotterdam, The Netherlands

  ⨯
• Elike Treffers-Westerlaken,

  Affiliation Laboratory of Experimental Tumor Immunology, Dept of Medical Oncology, ErasmusMC, Rotterdam, The Netherlands

  ⨯
• Giulia Fulci,

  Affiliation Brain Tumor Research Center, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• Sieger Leenstra,

  Affiliation Dept of Neurosurgery, Brain Tumor Center, ErasmusMC, Rotterdam, The Netherlands

  ⨯
• Clemens Dirven,

  Affiliation Dept of Neurosurgery, Brain Tumor Center, ErasmusMC, Rotterdam, The Netherlands

  ⨯
• Reno Debets,

  Affiliation Laboratory of Experimental Tumor Immunology, Dept of Medical Oncology, ErasmusMC, Rotterdam, The Netherlands

  ⨯
• Martine Lamfers

  * E-mail: m.lamfers@erasmusmc.nl

  Affiliation Dept of Neurosurgery, Brain Tumor Center, ErasmusMC, Rotterdam, The Netherlands

  ⨯